The FDA has granted traditional approval to Keytruda (pembrolizumab) in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback